Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake
http://www.reportsandreports.com/market-reports/japan-pharmaceutical-market-overview-regulatory-reforms-will-sti/
Introduction
The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma include the growing use of chronic high-value innovative treatments driven by an increasingly elderly population, the high proportion of the healthcare budget spent on pharmaceuticals compared to other developed pharmaceutical markets, and the low level of generic penetration.
Scope
Korosho determines the reimbursable drug price in Japan which is added to the National Health Insurance (NHI) list which must be followed by all insurers. The few non-reimbursed prescription drug groups include oral contraceptives, lifestyle drugs, and some vaccines.
Korosho implemented guidance for biosimilars approval in March 2009 and since then two biosimilars have been launched in Japan. Although this is a positive step for the biosimilars industry, the conservative and brand-loyal nature in Japan means that uptake will be slow, with only the larger, more well known players likely to succeed.
In contrast to the bleak prospects pervading the other major markets, Japan seems to have a brighter outlook with pharma companies having been less affected by job cuts and site closures.
Reasons to Purchase
The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma include the growing use of chronic high-value innovative treatments driven by an increasingly elderly population, the high proportion of the healthcare budget spent on pharmaceuticals compared to other developed pharmaceutical markets, and the low level of generic penetration.
Scope
- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Japan
- Assesses the size of Japan's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
- Examines Japan's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
- Quantifies Japan's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Korosho determines the reimbursable drug price in Japan which is added to the National Health Insurance (NHI) list which must be followed by all insurers. The few non-reimbursed prescription drug groups include oral contraceptives, lifestyle drugs, and some vaccines.
Korosho implemented guidance for biosimilars approval in March 2009 and since then two biosimilars have been launched in Japan. Although this is a positive step for the biosimilars industry, the conservative and brand-loyal nature in Japan means that uptake will be slow, with only the larger, more well known players likely to succeed.
In contrast to the bleak prospects pervading the other major markets, Japan seems to have a brighter outlook with pharma companies having been less affected by job cuts and site closures.
Reasons to Purchase
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Japan.
- Quantify the size and growth of the prescription pharmaceutical market in Japan, analyzing key therapy areas, brands and companies.
- Assess drivers and resistors of generic and biosimilars uptake in Japan as well as the level of erosion brands can expect to face post patent expiry.
